News Standigm and SK holdings C&C Release an AI-Based Target Identification Platform, iCLUE&ASK™, to Accelerate Drug Discovery Process

September 29, 2020

SEOUL, South Korea–(BUSINESS WIRE)–Standigm Inc. (“Standigm”), an artificial intelligence (AI)-based drug discovery company, and SK holdings C&C, Co., Ltd. (“SK holdings C&C”), a specialized Information and communications technology company, announced today that they opened their AI-based target identification platform, iCLUE&ASK™, on a trial basis to the public. The platform offers to prioritize protein targets for a query disease and provide the results with evidence through an interactive user interface.

News Standigm Collaborates with Excelra to enhance its AI-driven Drug Discovery Process

September 15, 2020

Hyderabad, India and Seoul, South Korea, Tuesday, 15th September, 2020: Standigm Inc., a company using artificial intelligence (AI) technology for drug discovery and development announced its collaboration with Excelra, a global data and analytics company for small molecule medicinal chemistry intelligence data.

News SK invests in Standigm for AI-based drug development

November 20, 2019

HONG KONG – SK Holdings Co. Ltd. invested KRW10 billion (US$8.6 million) in Standigm Inc., an artificial intelligence (AI)-powered biotech company based in Seoul, Korea. It is the second big investment Standigm has attracted this year after a KRW13 billion series B round in March.

Event BIO International Convention 2019

June 03, 2019

Date : June 3-6, 2019
Location : Philadelphia, PA, USA
Jinhan Kim, Standigm CEO is supposed to attend the BIO International Convention 2019.